The LncRNA promotes vessel co-option mediated antiagiogenic therapies (AATs) resistance

ABSTRACT: To identify the lncRNAs that may participate in antiangiogenic therapy (AAT) resistance, the bevacizumab-resistant HCT116 CRCLM xenografts were established.

ORGANISM(S): Homo sapiens

PROVIDER: GSE221557 | GEO | 2023/08/30

REPOSITORIES: GEO